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ABSTRACT
PACS-2 is a multifunctional sorting protein that mediates cell homeostasis. 
We recently identified PACS-2 in a functional genome-wide siRNA screen for novel 
regulators of the metalloproteinase ADAM17, the main sheddase for ligands of the 
ErbB receptor family. Of note, we showed that Pacs2-/- mice have significantly reduced 
EGFR activity and proliferative index in the intestinal epithelium. As EGFR signaling 
is highly mitogenic for intestinal epithelial stem cells, and plays essential roles in 
intestinal epithelial regeneration and tumor development, we have now examined 
the role of PACS-2 in these processes. Specifically, we analyzed the role of Pacs2-
deficiency in a DSS-induced colitis model as well as in the genetic ApcMin colon 
cancer model. We now report that loss of PACS-2 delays tissue regeneration after 
colonic injury with little effect on key inflammatory parameters. We did however not 
observe any apparent effects on tumor formation driven by excessive proliferative 
signaling downstream from APC-deficiency. Our findings reveal that the role of PACS-
2 in regulating ADAM17-mediated shedding is not an obligate requirement for the 
epithelium to respond to the strong inflammatory or tumorigenic inducers in the 
models assessed here.
INTRODUCTION
Phosphofurin acidic cluster sorting protein 2 
(PACS-2) is a multifunctional sorting protein involved 
in trafficking of various cargo molecules. PACS-2 
frequently acts in a complimentary manner to its close 
relative PACS-1, and the PACS protein family is central to 
ensuring the correct sorting and localization of a multitude 
of functionally diverse client proteins, with numerous 
downstream biological effects [1, 2]. We recently 
identified PACS-2 in a functional genome-wide siRNA 
screen for novel regulators of the transmembrane protease, 
a disintegrin and metalloproteinase-17 (ADAM17) [3]. 
We demonstrated that PACS-2 knockdown decreased 
the recycling of internalized ADAM17 protein, with a 
consequent reduction in the amount of active ADAM17 
on the cell surface [3]. 
The dynamics of cell-surface localized ADAM17 
are of importance because it cleaves a variety of cell-
surface molecules, a process termed ectodomain shedding. 
Notably, ADAM17 sheds ErbB ligands, leading to 
activation of ErbB family receptors (epidermal growth 
factor receptor (EGFR), ErbB2, ErbB3, ErbB4) to trigger 
cell growth, survival, and migration [4]. ADAM17 is 
thus an important player in the regulation of epithelial 
development, growth and tissue homeostasis, and its 
deregulation has been implicated in many human diseases 
[5]. By decreasing cell-surface levels of ADAM17, PACS-
2 knockdown led to a significant reduction in shedding 
of EGFR ligands. In vivo, this translated into reduced 
EGFR activition and proliferative index in the small 
intestinal epithelium and to a lesser extent in the colon 
of Pacs2-/- mice [3]. By controlling ADAM17 cell-surface 
availability, PACS-2 thus appears to fine-tune ADAM17 
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and ErbB activity, with potential functional effects on 
intestinal homeostasis.
Intestinal epithelial homeostasis relies on stem 
cells in the mucosal crypts, which continuously replenish 
cells lost from the apex of villi [6]. EGFR signaling is 
highly mitogenic for intestinal stem cells [7] and therefore 
central for intestinal homeostasis and regeneration. 
Importantly, ADAM17-mediated EGFR activation is 
essential for gut regeneration, and Adam17 and Egfr-
deficient mice are more susceptible to colitis induced 
by oral administration of the sulfated polysaccharide 
dextran sodium sulfate (DSS) [8-11]. Ingestion of DSS 
ablates the colonic epithelium, resulting in inflammation 
and subsequent repair of the damaged areas [12]. While 
the precise mechanisms governing ADAM17- and 
EGFR-mediated protection against DSS-induced colitis 
remain unknown, the ErbB ligands and known ADAM17 
substrates amphiregulin (AREG), epiregulin (EREG), 
and transforming growth factor (TGF)-α appear to be key 
effectors [8, 9, 13-15]. 
We hypothesized that as a regulator of ADAM17 
and EGFR activities, loss of PACS-2 would influence 
intestinal epithelial pathologies. To this end, we treated 
Pacs2-/- mice and wildtype littermates with DSS and 
evaluated disease progression and effects on intestinal 
histology. Another process that relies on EGFR signaling is 
the development of intestinal tumors [16], which originate 
from crypt stem cells [17]. Accordingly, we investigated 
the effects of PACS-2 loss in the ApcMin mouse model of 
colorectal cancer. ApcMin mice mimic familial colorectal 
cancer in patients with only one functional adenomatous 
polyposis coli (APC) gene allele, and APC is furthermore 
mutated in most sporadic human colorectal cancers [18]. 
As in humans, loss of heterozygosity of the remaining 
wildtype Apc allele results in the formation of multiple 
adenomas, and the ApcMin/+ mouse is therefore a commonly 
used model of colorectal cancer [19]. 
RESULTS
Pacs2-/- mice show no significant changes in 
susceptibility to DSS-induced colitis
To evaluate the effects of PACS-2 on intestinal 
inflammation and regeneration, groups of male Pacs2-/- 
and littermate Pacs2+/+ (control) mice were administered 
2.3% DSS in the drinking water, followed by 5 days 
on regular water (Figure 1A). Quantitative RT-PCR of 
mRNA isolated from colonic tissue of control and Pacs2-
/- mice verified the Pacs2-deficiency of Pacs2-/- mice and 
importantly, revealed a small but statistically significant 
increase in the mRNA expression of PACS-1, the other 
member of the PACS protein family (Figure 1B). Of note, 
Pacs2 mRNA expression was not significantly altered 
during DSS-induced colitis (Figure 1C). During the course 
of colitis, Pacs2-/- mice tended towards poorer survival 
than littermate controls (35 % vs. 61 % survival at day 
10, respectively; Figure 1D); however, this difference was 
not statistically significant (p = 0.08). Colon shortening, a 
macroscopic parameter of colitis severity, was observed to 
a similar extend in Pacs2-/- and control mice (Figure 1E). 
Additionally, we found no significant difference in weight 
loss in Pacs2-/- mice as compared to controls (Figure 1F). 
To assess disease severity in more detail, we 
calculated the Disease Activity Index (DAI), adapted 
from the method first described by Cooper et al. [12]. The 
DAI is the average of three independent scores describing 
weight loss, stool consistency and stool blood content. The 
scoring system employed is outlined in Table 1. Although 
computation of the DAI showed a slightly increased 
disease severity in Pacs2-/- mice as compared to controls, 
the change was not statistically significant (Figure 1G). 
Thus, while there was a tendency toward worse disease 
progression in Pacs2-/- mice undergoing DSS-induced 
colitis, these changes were not significant.
Pacs2-/- mice show comparable inflammation and 
tissue damage during DSS-induced colitis, but a 
slight delay in regeneration
Histological examination revealed severe tissue 
damage with numerous mononuclear cells infiltrating the 
lamina propria of colons on day 6 of the DSS-induced 
colitis model in both control and Pacs2-/- mice (Figure 
2A). Day 6 was the time of most severe tissue damage, 
with some tissue regeneration being seen in histological 
sections from day 10 (Figure 2A). Tissue damage was 
quantified by a method adapted from Obermeier et al. [20]. 
Histological sections were scored blindly using the criteria 
outlined in Table 2 and a histology score was calculated 
by combining the epithelial damage score and the 
inflammation score. Consistent with the hematoxylin and 
eosin (H&E) images presented, there was no difference 
in the histology score between groups on day 6 of DSS-
induced colitis (Figure 2B, left graph). On day 10, the 
histology score was significantly higher in Pacs2-/- mice as 
compared to control mice (Figure 2B, right graph), which 
indicates a slight delay in tissue regeneration. 
 To examine the regenerative response of the 
intestinal epithelium to DSS treatment, we assessed 
the level of activated EGFR (Tyr1068 phosphorylated) 
by immunofluorescence staining of histological colon 
sections from Pacs2-/- and control mice (Figure 3A and 
3B). While no difference was observed at day 6 after DSS 
treatment, the level of activated EGFR was significantly 
reduced at day 10 of the DSS-induced colitis model in 
Pacs2-/- mice compared to control mice. Yet, proliferation 
of the intestinal epithelial cells was not significantly 
affected at any of the time points, as assessed by Ki67 
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Table 1: Scoring system used for calculation of Disease Activity Index
Score Weight loss (%) Stool consistency Blood in stools
0 ≤ 1 Normal Negative Hemoccult test
1 > 1 - ≤ 5 Soft but formed Positive Hemoccult test
2 > 5 - ≤ 10 Soft Visibly bloody stool
3 > 10 - ≤ 20 Diarrhea Rectal bleeding
4 > 20 - -
Disease Activity Index = Average of the sum of the three scores. The scoring system is adapted from that described by Cooper 
et al. [12]. 
Figure 1: Pacs2-/- mice show no significant changes in susceptibility to DSS-induced colitis. A. Schematic of the DSS 
treatment regimen and data collection. Littermate Pacs2+/+ (control, n = 21) and Pacs2-/- (n = 17) mice received 2.3% DSS in their drinking 
water for five days, followed by five days on regular water. Mice were weighed on days 0, 2, and 5-10, and stool consistency and blood 
content additionally monitored from days 5-10. B. Quantitative real-time PCR analysis of Pacs2 and Pacs1 mRNA levels in the colon of 
control (n = 5) and Pacs2-/- mice (n = 4). Gapdh served as a control for normalization. C. Quantitative real-time PCR analysis of Pacs2 
mRNA levels in colonic tissue isolated from Pacs2+/+ mice at Day 0, 6 and 10 during DSS-induced colitis. D. Kaplan-Meier plot depicting 
the percentage survival of control (61 %) versus Pacs2-/- (35 %) mice. Survival was evaluated by log-rank (Mantel-Cox) test (control, n 
= 21; Pacs2-/-, n = 17). E. Changes in colon length in control and Pacs2-/- mice on day 6 of the DSS protocol (control, n = 9; Pacs2-/-, n = 
4). F. Daily changes in body weight during DSS-induced colitis. Changes in body weight percentage were calculated by normalizing body 
weight at the specific day to the body weight at day 0 (control, n = 21; Pacs2-/-, n = 17). G. The Disease Activity Index (DAI) was calculated 
as the average of the weight loss score, stool score, and bleeding scores (control, n = 21; Pacs2-/-, n = 17). All data were pooled from three 
independent experiments. Graphs represent the mean ± S.E.M; ***p < 0.005 analyzed by two-way ANOVA.
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Figure 2: Pacs2-/- mice show comparable inflammation and tissue damage during DSS-induced colitis. Histological 
sections were scored blindly using the criteria outlined in Table 2. A. Representative images of colonic specimens from control and Pacs2-
/- mice isolated at day 6 and day 10. Scale bar overview pictures = 1 mm. Scale bar detail figures = 0.1 mm. B. Dot plots show the histology 
score, calculated as the sum of the epithelial damage score and the inflammation score. The individual scores were calculated as described 
in Table 2. All data represent the mean ± S.E.M. and were analyzed by unpaired Student’s t-test (n = 6-13 as indicated). Data were pooled 
from three independent experiments. 
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staining (Figure 3C and 3D). Since PACS-2 coordinates 
multiple cell survival pathways [2], we assessed the 
number of apoptotic cells after DSS treatment. In line with 
previous reports [21, 22], Pacs2-/- intestinal epithelial 
cells exhibited a marked increase in the number of 
apoptotic cell (Figure 3E and 3F). 
For further evaluation of tissue damage and 
inflammation, mRNA levels of the inflammatory genes 
tumor necrosis factor (Tnf)α, interleukin (Il)-6 and 
chemokine (C-X-C motif) ligand (Cxcl)1, as well as the 
EGFR ligands Areg, Ereg and Tgfα were analyzed by 
qRT-PCR. All transcripts, except Tgfα were upregulated 
on day 6 in the colons of both control and Pacs2-/- DSS-
treated mice, with no differences in expression of any 
of the genes between genotypes (Supplementary Figure 
1A and 1B). Likewise, expression of the fibrotic marker 
collagen type 1 (Col1)a1 was equally increased in Pacs2-
/- and control mice after DSS treatment (Supplementary 
Figure 1C). These findings were supported by ELISA data, 
demonstrating comparable AREG and TNFα levels in 
supernatants from tissue explant cultures established from 
mice sacrificed at day 6 of the DSS-induced colitis model 
(Supplementary Figure 1D).
Pacs2-deficiency has no apparent effects on 
intestinal tumor growth in the ApcMin mouse model 
of colorectal cancer
Another process that relies on EGFR signaling is the 
development of intestinal tumors. We therefore evaluated 
the effects of Pacs2-deficiency in the ApcMin mouse model 
of colorectal cancer. The successful generation of ApcMin/+ 
Pacs2-/- mice was confirmed by western blot (Figure 4A) 
and qRT-PCR analysis (Figure 4B). PACS-2 was equally 
expressed in tumor and non-tumor tissues from the colons 
of ApcMin/+ Pacs2+/+ (control) mice as shown by western 
blot (Figure 4A), and confirmed by qRT-PCR analysis 
(Figure 4C). In contrast to our findings in the DSS-induced 
colitis model (Figure 1B), Pacs2-deficiency did not affect 
the small intestinal expression of PACS-1 (Figure 4B). 
Moreover, there were no differences in the overall colonic 
APC-regulated β-catenin expression levels between 
littermate control and ApcMin/+ Pacs2-/- mice (Figure 4A). 
Gross examination of isolated ileal tissue from 
control and ApcMin/+ Pacs2-/- mice revealed no obvious 
differences in tumor load (Figure 5A). This was confirmed 
by quantification of the average total number of adenomas 
per mouse (Figure 5B). We found a similar distribution 
of tumors in ApcMin/+ Pacs2-/- versus control mice, based 
on evaluation of the average number of adenomas in the 
proximal, middle and distal segments of the small intestine 
(Figure 5C) and entire colon (Figure 5D). Likewise, there 
were no changes in total tumor area per mouse (Figure 5E) 
or in tumor size, quantified as average adenoma diameter 
(Figure 5F).
PACS-2 loss does not affect tumor morphology, 
β-catenin expression or cell proliferation in the 
ApcMin model of colorectal cancer
H&E staining of histological sections of adenomas 
in the distal small intestine revealed no obvious 
morphological changes between control and ApcMin/+ 
Pacs2-/- mice (Figure 6A). To confirm constitutive Wnt 
signaling in tumors upon APC mutation, we performed 
immunohistochemistry for β-catenin. β-catenin was 
localized to the perinuclear region in tumors, but cell 
membrane-associated in the surrounding non-tumor tissue, 
with no apparent differences between control and ApcMin/+ 
Pacs2-/- mice (Figure 6B). Also, Ki67 immunostaining 
showed comparable cell proliferation in both genotypes 
(Figure 6C). 
DISCUSSION
We recently reported that PACS-2 regulates cell-
surface availability of ADAM17, thereby fine-tuning 
ADAM17 activity and downstream ErbB signaling [3]. 
We observed a marked reduction in phosphorylated 
EGFR levels and proliferative index in the small intestinal 
epithelium and to a lesser extent in the colonic epithelium 
of Pacs2-/- mice. Furthermore, Pacs2-/- mice had abnormal 
intestinal histology with a decrease in villus/crypt 
ratio of the small intestine [3]. Interestingly, intestinal 
Table 2: Scoring system used for calculation of histology score
Score Epithelial Damage (E) Inflammation (I)
0 Normal morphology Normal morphology
1 Loss of goblet cells Mild inflammation
2 Loss of goblet cells in large areas/smaller areas with loss of crypts Moderate inflammation
3 Moderate loss of crypts Severe inflammation
4 Loss of crypts in large areas -
Histology score = E+I. The scoring system is adapted from that described by Obermeier et al. [20]. 
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Figure 3: Evaluation of the regenerative response of intestinal epithelial cells in DSS-treated Pacs2-/- mice. A. 
Representative images of colonic specimens from control and Pacs2-/- mice isolated at day 6 and day 10 and stained for phosphorylated 
EGFR (Tyr1068) and nuclear DAPI stain. B. The graph shows the pEGFR fluorescence intensity quantified along a line across colonic 
crypts (represented by the dotted line in A) on 5 equally positioned, random confocal images from each of 5 control and 5 Pacs2-/- mice. 
C. Representative images of colonic specimens from control and Pacs2-/- mice isolated at day 6 and day 10 and stained for Ki67 positive 
proliferating cells. D. The graph shows Ki67 positive cells represented as the percentage diaminobenzidine (DAB) positive area per total 
hematoxylin stained nuclear area from 5 equally positioned, random images from each of 5 control and 5 Pacs2-/- mice. E. Representative 
images of colonic specimens from control and Pacs2-/- mice isolated at day 6 and day 10 and stained for apoptotic cells by ApopTag. F. The 
graph shows the number of apoptotic cells per mm2 counted from 3 equally positioned, random images from each of 5 control and 5 Pacs2-
/- mice. Scale bars = 50 µm. All graphs show mean values ± SEM analyzed by unpaired two-tailed Student’s t-test. **p < 0.01.
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Figure 4: Characterization of ApcMin/+ Pacs2-/- mice. A. Representative cropped western blots showing expression of PACS-2 (top 
panel) and β-catenin (middle panel) in tumor (T) and non-tumor (NT) colonic tissue samples from littermate ApcMin/+ Pacs2+/+ (control) 
and ApcMin/+ Pacs2-/- mice. Actin served as loading control. B. Quantitative real-time PCR analysis of Pacs2 (left) and Pacs1 (right) mRNA 
levels in the small intestine of control and ApcMin/+ Pacs2-/- mice (control, n = 7; ApcMin/+ Pacs2-/-, n = 3). Gapdh served as a control for 
normalization. C. Quantitative real-time PCR analysis of Pacs2 mRNA levels in tumor (T) and non-tumor (NT) tissue isolated from small 
intestine of ApcMin/+ Pacs2+/+ mice (NT, n = 5; T, n = 4). All data represent the mean ± S.E.M and were analyzed by unpaired Student’s 
t-test; ***p < 0.001.
Figure 5: Pacs2-deficiency has no apparent effects on intestinal tumor growth in the ApcMin mouse model of colorectal 
cancer. A. Representative gross images of ileum specimens from control and ApcMin/+ Pacs2-/- mice. White arrowheads indicate tumors. 
TM = tunica muscularis. Scale bar = 500 µm. Analysis of tumor number B., tumor distribution in the proximal, middle, and distal small 
intestine C. and colon D., tumor area E. and tumor size F. in control (n = 21) and ApcMin/+ Pacs2-/- (n = 19) mice. All data represent the mean 
± S.E.M (B, E, F) or the mean ± the minimum/maximum data points (C, D) and were analyzed by unpaired Student’s t-test.
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abnormalities have been reported in a number of studies 
of genetic alterations in the ADAM17/EGFR axis [9, 23-
28]. While these phenotypes are not directly comparable 
to those observed in Pacs2-deficient mice, we found the 
similarities interesting. Apart from maintaining normal 
intestinal homeostasis, ADAM17 and ErbB signaling is 
of great importance for intestinal epithelial regeneration, 
and in the development of intestinal tumors [7-11, 16, 
28, 29]. Here, although we observed a slight effect of 
Pacs2-deficiency in the context of intestinal inflammatory 
damage, loss of the ADAM17 fine-tuning function of 
PACS-2 was not sufficient to influence tumor formation 
driven by excessive Wnt signaling in the ApcMin model of 
colorectal cancer.
Several studies have demonstrated that Adam17 and 
Egfr-deficient mice are more susceptible to colitis induced 
by oral administration of DSS. Typical findings include 
increased weight loss, higher mortality, and more severe 
Figure 6: PACS-2 loss does not affect tumor morphology, ß-catenin expression or cell proliferation in the ApcMin model 
of colorectal cancer. Representative histological images of ileal adenomas from ApcMin/+ Pacs2+/+ (control) and ApcMin/+ Pacs2-/- mice. A. 
depicts H&E staining (scale bars = 100 µm), B. immunohistochemistry for ß-catenin (upper panel 10x, scale bars = 100 µm; lower panels 
scale bars = 50 µm; white arrowhead = nuclear staining; black arrow = membrane staining), and C. shows staining for the proliferation 
marker Ki67 (upper panel 10x, scale bars = 100 µm; lower panel scale bars = 50 µm).
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inflammation and ulceration in these animals [8-11]. We 
observed a tendency towards poorer overall survival and 
slightly increased disease score in the Pacs2-/- mice, but 
none of the changes were statistically significant. Also, 
while loss of ADAM17 has been shown to significantly 
impact both inflammation and regeneration in the DSS-
induced model of colitis [8], PACS-2-deficient animals 
only displayed indications of delayed regeneration in this 
model. This modest impact of Pacs2-deficiency likely 
results from its fine-tuning effects on ADAM17, whereby 
loss of PACS-2 only decreases ADAM17 cell-surface 
levels and intestinal EGFR activation by approximately 
50% [3]. Thus, PACS-2 loss cannot be expected to have 
as severe effects as loss of ADAM17 or EGFR. Indeed, 
although we did find significantly reduced pEGFR levels 
in the colon of Pacs2-/- mice as compared to control 
mice at day 10 of the DSS-induced colitis model, no 
significant difference in the number of proliferating 
colonic epithelial cells was observed. Corroborating these 
marginal effects, the previously reported reduction in 
EGFR phosphorylation and intestinal cell proliferation in 
PACS-2-deficient mice was much less pronounced in the 
colon as compared to the small intestine [3].
We observed no apparent effects of Pacs2-deficiency 
in the ApcMin model of colorectal cancer when assessing 
tumor number, size or histology. While EGFR signaling is 
strongly implicated in the development of intestinal tumors 
[16], it appears that loss of the fine-tuning effects of PACS-
2 is also not sufficient to impede tumor development or 
progression. It is possible that the strong proliferative 
signaling resulting from APC-deficiency overrides the 
modest anti-proliferative effects caused by the reduction in 
EGFR activity in Pacs2-/- animals. Additionally, it has been 
shown that systemic overexpression of ADAM17 in mice 
does not lead to enhanced shedding activity or any overt 
abnormalities [30], and expression of only 5% of normal 
ADAM17 levels is enough to overcome the embryonic 
lethality associated with complete ADAM17 knockout in 
mice [8]. Hence, the amount of ADAM17 appears not to 
be rate-limiting, as long as it is above a certain threshold. 
It is therefore likely that the fine-tuning effects of PACS-2 
serve to uphold a homeostatic balance in ADAM17 levels, 
and that the loss of this has little functional consequence 
when the inflammatory or proliferative signals are very 
potent.
Worth mentioning, we found a small but statistically 
significant increase in Pacs1 expression in the colon of 
DSS-treated Pacs2-/- mice as compared to control mice. 
With a high degree of homology and frequently shared 
cargo of PACS proteins, this could indicate a potential 
functional compensation by PACS-1 upon loss of PACS-2 
expression. Yet, no difference in PACS-1 mRNA levels 
were detected in the small intestine of control and ApcMin/+ 
Pacs2-/- mice. Whether PACS-1 exerts similar regulatory 
effects on ADAM17-mediated EGFR activation as PACS-
2 is a present unknown. For future studies, it would be 
interesting to investigate such potentially redundant 
functions as well as the phenotypic impact of deleting 
both genes.
Moreover, PACS-2 serves numerous other functions 
unrelated to ADAM17 and ErbB signaling. The loss of 
these other functions may serve to promote inflammation 
or tumor growth, and in this way neutralize any anti-
inflammatory or anti-tumorigenic effects caused by 
reduced ADAM17 and ErbB signaling. Importantly, 
PACS-2 exerts highly complex regulatory functions on 
multiple cell death pathways (for a recent review see 
[2]). For example, PACS-2 is a key effector in TRAIL-
mediated apoptosis, and loss of PACS-2 was shown to 
desensitize human colon cancer cells to TRAIL-induced 
apoptosis [31]. On the other hand, PACS-2 promotes 
cell survival following DNA damage, as exemplified 
by increased radiation-induced apoptosis in Pacs2-/- 
thymocytes [21, 22]. In line with the later findings, we 
observed a significant increase in the number of apoptotic 
mucosal cells in the colon of DSS-treated Pacs2-/- mice as 
compared to control mice. 
 Although the sample size was too small to 
determine the relative importance, it has been reported 
that the human PACS2 locus is susceptible to loss of 
heterozygosity in colon cancer patients [32]. Also, a small 
selection of clinical material showed loss of PACS-2 in 4 
out of 8 tumor samples, with PACS-2 expression being 
preserved in the surrounding non-tumor tissue [31]. While 
this finding needs validation in a larger patient cohort, a 
selective pressure for the loss of PACS-2 expression in 
tumor cells could indicate that the pro-apoptotic functions 
of PACS-2 may dominate effects on tumor formation and 
growth.
In conclusion, our data show that the effect of 
PACS-2 on ADAM17-mediated EGFR activation has 
negligible impact on DSS-induced colitis and the ApcMin 
model of cancer. These observations suggest that as a fine-
tuner of ADAM17 and ErbB activities, Pacs2-deficiency 
has no notable outcome on intestinal epithelial pathologies 
where the induction of inflammation or cell proliferation is 
sufficiently strong and the amount of ADAM17 not rate-
limiting.
MATERIALS AND METHODS
Reagents and antibodies
DSS (Molecular weight 36,000-50,000 kDa) was 
obtained from MP Biomedicals (catalog no. 02160110). 
Hemoccult Test Kit was obtained from Beckman Coulter. 
Complete EDTA-free protease inhibitor cocktail was from 
Roche. 
Primary antibodies used for immunohistochemistry 
(IHC) and western blotting (WB) were: mouse anti-actin 
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(Millipore MAB1501R, diluted 1:1000 for WB), mouse 
anti-β-catenin (BD Transduction Laboratories #610154, 
diluted 1:1000 for IHC and 1:2000 for WB), rabbit anti-
Ki67 (Abcam Ab15580, diluted 1:500 for IHC), rabbit 
anti-EGFR phosphorylated at Tyr1068 (Abcam Ab40815, 
diluted 1:200 for IHC). Rabbit anti-PACS-2 18193 was 
previously described [21], and was diluted 1:1000 for WB.
Enzyme-linked immunosorbent assay (ELISA) 
kits used for analysis of ex vivo colonic tissue culture 
supernatants were mouse amphiregulin DuoSet ELISA 
(R&D Systems DY989) and mouse TNF-α ELISA Ready-
SET Go! (eBioscience 88-7324).
The primers used for Pacs2 genotyping were 5′-
ATG CAT ACC TGC CCT TAG CAG AGG-3′, 5′-TGG 
AGT CTG AGG TTG AGG CCT TGA G-3′, and 5′-
ATG GCG TTA CTT AAG CTA GCT TGC-3′. Primers 
for ApcMin/+ genotyping were 5′-GCC ATC CCT TCA 
CGTTAG-3′, 5′-TTC CAC TTT GGC ATA AGG C-3′ and 
5′-TTC TGA GAA AGA CAG AAG TTA-3′. All primers 
were obtained from TAG Copenhagen.
Animals
All animal studies were approved by the Danish 
Animal Inspectorate (License no. 2014-15-0201-
00237). The authors confirm that all the experiments 
were performed in accordance with Danish guidelines 
and regulations for scientifically and ethically approved 
experimentation. 
All mice were maintained in a climate-controlled 
room at a temperature of 22 ± 2°C and a relative humidity 
of 50 ± 5% under a 12-hour light/dark cycle and fed a 
standard diet. Pacs2-/- and Pacs2+/+ littermate mice were 
co-housed and all handling of the mice, e.g. changing of 
cages, was done under non-sterile conditions to ensure 
similar microbiota in individual cages. Pacs2-/- mice on 
the C57BL/6 background have been previously described 
[31] and were from The Jackson Laboratory. ApcMin/+ 
mice (C57BL/6 background) were acquired through The 
Jackson Laboratory. ApcMin/+ Pacs2-/- mice were obtained 
by crossbreeding between ApcMin/+ mice and Pacs2-/- mice. 
The founder mice were viable and exhibited normal 
growth. All genotyping was performed by polymerase 
chain reaction (PCR) using genomic DNA prepared from 
mouse-tails, using the primers listed above. 
DSS-induced mouse model of colitis
Littermate groups of male Pacs2+/+ (control) and 
Pacs2-/- mice (8 to 16 weeks old) received 2.3% DSS 
(molecular weight 36,000-50,000 kDa, MP Biomedicals) 
in their drinking water for 5 days, followed by 5 days on 
regular drinking water. The optimal DSS concentration 
was carefully determined through several dose-response 
experiments starting with 2% DSS, which was the dose 
used in the study of hypomorphic Adam17ex/ex mice [8]. 
The final experiment with 2.3% DSS was repeated three 
times, including a total of 21 control and 17 Pacs2-/- mice. 
Mice were observed and weighed on days 0, 2, and 5-10. 
There was no significant difference in initial body weight 
between the two groups. Percentage weight was calculated 
as (weight on a given day / weight on day 0) x 100. Stool 
consistency and stool blood content were monitored on 
days 5-10 (see Figure 1B). Mice were sacrificed upon 
reaching the humane endpoints defined as more than 
20% weight loss, severe pain or severe rectal bleeding. 
All surviving mice were euthanized on day 10 and entire 
colons were isolated and processed for histological 
analysis (see below).
Weight loss, stool consistency, and stool blood 
content were scored as described in Table 1, adapted from 
the method first described by Cooper et al. [12]. Stool 
blood content was first determined by visual inspection 
of stool. If no gross blood was visible, the presence of 
occult blood was determined using a Hemoccult Test 
Kit (Beckman Coulter). The DAI was calculated as the 
average of the three scores [12]. In the few cases where it 
was not possible to acquire a stool sample, the weight loss 
score was substituted for the DAI. To assess tissue damage, 
we employed a method adapted from that previously 
described [20]. Histological sections of entire colons were 
scored blindly and independently by two researchers, one 
of them a trained pathologist, and subsequently compiled. 
Epithelial damage and extent of inflammation were scored 
using the criteria outlined in Table 2. An overall histology 
score was then calculated as the sum of the epithelial 
damage score and the inflammation score [20].
Analysis of intestinal tumors in the ApcMin mouse 
model of colorectal cancer
Eighteen-week old littermate ApcMin/+ Pacs2+/+ 
(control, n = 22) and ApcMin/+ Pacs2-/- (n = 19) mice 
(mixed sexes) were sacrificed, and the entire intestine was 
excised and divided into colon and three equal segments of 
small intestine: proximal, medial, and distal representing 
duodenum, jejunum and ileum, respectively. All regions 
were opened longitudinally and examined macroscopically 
for number, size and location of adenomas, using a 
stereomicroscope. Tissues were subsequently processed 
for histological analysis (see below). 
Histological analysis
Intestinal tissues were fixed in 4% paraformaldehyde 
(Sigma-Aldrich) dissolved in phosphate-buffered saline 
(PBS), embedded in paraffin, and sectioned to a thickness 
of 3.5 μm. H&E and IHC staining for β-catenin and Ki67 
were performed as previously described [3]. The sections 
were scanned using a NanoZoomer 2.0-HT Digital slide 
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scanner C9600 (Hamamatsu) and analyzed with NDP.
view 2 software. Ki67 positive proliferating cells were 
quantified as the percentage diaminobenzidine (DAB) 
positive area per total hematoxylin stained nuclear area, 
using ImmunoRatio, a publicly available application 
for quantitative image analysis [33]. Activated EGFR 
levels were assessed as described previously [3], using 
an antibody against EGFR phosphorylated on Tyr1068 
and Alexa Fluor 488 conjugated secondary anti-rabbit 
antibody, and measuring the fluorescence intensity along 
a line across colonic crypts. Apoptotic intestinal epithelial 
cells were detected using the ApopTag® Peroxidase In 
Situ Oligo Ligation (ISOL) Apoptosis Detection Kit as 
recommended by the manufacturer (Chemicon), and 
quantified using Axiovision Software (Zeiss) and manual 
counting of stained cells per mm2 tissue from 3 randomly 
chosen mucosal areas. For quantifications, colon sections 
from 4-5 controls and 4-5 Pacs2-/- mice were used.
Western blotting
Intestines were opened longitudinally, and 
macroscopic tumors as well as non-tumor tissue was 
isolated. Protein extracts from non-tumor and tumor tissue 
were prepared using RIPA buffer (50 mM Tris pH 7.4; 150 
mM NaCl; 0.1% SDS; 1% Triton X-100; 0.5% sodium 
deoxycholate; 1 mM EDTA, with protease inhibitor 
cocktail), and adjusted to equal concentration. Expression 
of PACS-2 and β-catenin were subsequently evaluated 
by western blot analysis using standard procedures, as 
described [3].
Quantitative real-time PCR
Colonic tissue or intestinal macroscopic tumors 
and corresponding non-tumor tissue were isolated from 
intestines. To stabilize RNA, tissue was immersed in 
RNAlater solution (Sigma-Aldrich) and then snap-
frozen in liquid nitrogen. Total RNA was extracted 
from tissues using the GeneJET RNA Purification Kit 
(ThermoFisher Scientific) according to the manufacturer´s 
instructions. Total RNA (1-2 µg) was reverse transcribed 
using RevertAid Reverse Transcriptase (ThermoFisher 
Scientific, cat. no. EP0441), and quantitative real-time 
PCR (qRT-PCR) was performed on a LightCycler480 
PCR machine (Roche) using Maxima SYBR Green/ROX 
qPCR Master Mix (2X) (ThermoFisher Scientific, cat. no. 
K0221), according to the manufacturer’s instructions. The 
following combinations of primers were used to analyze 
the expression of Pacs2: 5´-CCT GGC TCT GAC CTT 
CTC TC-3´ and 5´-CCA GGA TCG TCC TGT TCT TG-
3´. Pacs1 primers were: 5´-CAG CAC CTT TCT TGA 
TTC TGC-3´ and 5´-TCC ATT GAC ATA CTG CAT 
CAC A-3´. Primers for gapdh were: 5´-AAG GTC ATC 
CCA GAG CTG AA-3´and 5´-CTG CTT CAC CAC 
CTT CTT GA-3´. Areg primers were: 5´-TCC AAG ATT 
GCA GTA GTA GCT GTC-3´ and 5´- CCC TGA AGT 
ATC GTT TCC AAA G-3´. Ereg primers were: 5´-CAC 
CGA GAA AGA AGG ATG GA-3´and 5´-TCA CGG TTG 
TGC TGA TAA CTG-3´. Tgfα primers were: 5´-CCT GGT 
GGT GGT CTC CAT T-3´ and 5´-CAG TGT TTG CGG 
AGC TGA-3´. Tnfα primers were: 5´-CTG TAG CCC 
ACG TCG TAG C-3´and 5´-TTG AGA TCC ATG CCG 
TTG-3´. Il-6 primers were: 5´-GCT ACC AAA CTG GAT 
ATA ATC AGG A-3´and 5´-CCA GGT AGC TAT GGT 
ACT CCA GAA-3´. Cxcl1 primers were: 5´-GAC TCC 
AGC CAC ACT CCA AC-3´and 5´-TGA CAG CGC AGC 
TCA TTG-3´. Col1a1 primers were 5´-CTG ACT GGA 
AGA GCG GAG AGT-3´ and 5´-GAC GGC TGA GTA 
GGG AAC AC-3´. Data were analyzed using the 2−∆∆CT 
methodology, as described [34].
Ex vivo cultures of colonic explants
Tissue explants sized approximately 1 cm were 
harvested from the proximal colon and washed twice 
in cold PBS containing 100 µg/ml of streptomycin and 
100 U/ml penicillin (with incubation for at least 10 min). 
After washing the tissue specimens, cultures were placed 
in a 24-well plate in 1 ml of DMEM with 100 µg/ml of 
streptomycin and 100 U/ml penicillin. After 24 hours, 
supernatants were collected, centrifuged at 1000 x g to 
eliminate debris, and analyzed by ELISA. 
ELISA
Soluble TNFα and AREG levels were measured 
by ELISA in cell-free ex vivo colonic tissue culture 
supernatants according to the manufacturer´s instructions. 
Absolute values were normalized to tissue weight of 
colonic culture explants used in the experiment. 
Statistical analysis
Unless otherwise stated, all data represent the 
mean ± standard error of the mean (S.E.M.). Data were 
analyzed by unpaired Student’s t-test, analysis of variance 
(ANOVA) with Tukey’s post-test, or log-rank (Mantel-
Cox) test, as appropriate, using GraphPad Prism version 
6.00 for Macintosh (GraphPad Software). In all cases, p < 
0.05 was considered statistically significant. 
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